# Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation

> **NCT00789308** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 24 (actual)

## Conditions studied

- Diabetes Mellitus, Type I

## Interventions

- **DRUG:** Low Molecular Weight Sulfated Dextran (LMW-SD)
- **DRUG:** Heparin
- **DRUG:** CellCept® (Mycophenolate mofetil) OR Rapamune® (Sirolimus)
- **DRUG:** Prograf® (Tacrolimus) OR Cyclosporine
- **DRUG:** Thymoglobulin® (Anti-thymocyte Globulin) - at first transplant
- **DRUG:** Simulect® (Basiliximab) - at 2nd or 3rd transplant
- **DRUG:** Klexane® (Enoxaparinsodium)
- **DRUG:** Trombyl® or Albyl-E® (Acetylsalicylicacid- ASA)
- **DRUG:** Enbrel® (Etanercept)

## Key facts

- **NCT ID:** NCT00789308
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07-11
- **Primary completion:** 2013-07
- **Final completion:** 2014-08-21
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-09-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00789308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00789308, "Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00789308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*